Quale sarebbe il prezzo per Novo Nordisk A/S (NOVO-B)

Il prezzo per Novo Nordisk A/S (NOVO-B) è $43.92

Qual è la capitalizzazione di mercato per Novo Nordisk A/S (NOVO-B)

La capitalizzazione di mercato per Novo Nordisk A/S (NOVO-B) è $195.10B

Novo Nordisk A/S (NOVO-B) Rapporto P/B

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Anno	Rapporto P/B	Cambia
Non abbastanza dati per le date fornite.

Anno

Rapporto P/B

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rapporto P/B	Differenza del rapporto P/B	Il paese
Eli Lilly and Company LLY.US	30.4982	328.79%	US
Johnson & Johnson JNJ.US	7.6344	7.34%	US
AbbVie Inc. ABBV.US	-76.5033	-1,175.60%	US
Roche Holding AG RO.SW	8.4776	19.19%	CH
Merck & Co., Inc. MRK.US	8.7106	22.47%	US

Azienda

Rapporto P/B

Differenza del rapporto P/B

Il paese